GIST After Imatinib, the 20-Year Wait to Beat Sunitinib, and the November 30th FDA Decision on Bezuclastinib

I chose the photo above, a ridge of trees breaking through a sea of cloud at sunrise, because it is the truest picture I know of the second line of gastrointestinal stromal tumor treatment. Sunitinib became the second drug for GIST in January 2006, approved as Sutent for people whose tumors had grown through imatinib, and for 20 years it has been the cloud line. Every drug tested against it since has come out level with it or below it, including Qinlock in 2022. Cogent Biosciences named its trial Peak, and in November 2025 it reported the first result to break through. Adding its pill bezuclastinib to sunitinib held tumors still for a median of 16.5 months, against 9.2 on sunitinib alone.

The FDA accepted the application on May 28, 2026 with priority review and set November 30, 2026 as its target date. Cogent says the agency does not plan an advisory committee and has not raised any review issues. For someone whose imatinib has stopped working, or who is already on sunitinib, the question before the end of the month is practical. This post lays out what the PEAK trial measured and which patients it did not include. It then covers what the combination asks of the liver and where GIST families turn for second opinions, money and company.

Why Has No GIST Drug Beaten Sunitinib in 20 Years?

Every approved GIST drug after imatinib earned its place by beating a sugar pill, not another drug. The sunitinib label describes a 312-patient trial in which people whose GIST had grown on imatinib went a median of 24.1 weeks before progression or death, against 6.0 weeks on placebo. Stivarga, approved for the third line in 2013, posted 4.8 months against 0.9 in the GRID trial. Qinlock, approved for the fourth line in May 2020, posted 6.3 months against 1.0 in INVICTUS. Those placebo figures are a reminder of how fast an untreated resistant GIST moves.

The one trial that put 2 real drugs head to head came up short. INTRIGUE randomized 453 people after imatinib to Qinlock or sunitinib, and median progression-free survival was 8.0 months on Qinlock against 8.3 on sunitinib (Bauer et al., 2022). Qinlock caused fewer severe side effects, 41.3% against 65.6%, but it did not keep tumors still any longer, so sunitinib stayed the second-line standard and Qinlock stayed in the fourth line.

Reading down the ladder shows something the headline numbers hide. Sunitinib alone has done better in every trial since its own, from 5.5 months in 2006 to 8.3 months in INTRIGUE to 9.2 months in PEAK. The trials differ in who they enrolled and in the sunitinib schedule, since PEAK gave 37.5mg every day while the 2 older trials used 50mg with 2 weeks off. Whatever the reasons, the PEAK comparison sits on the strongest sunitinib arm ever recorded, which makes the 16.5-month figure harder to dismiss, not easier.

PEAK enrolled 413 adults whose GIST had grown on imatinib or who could not tolerate it, and its ClinicalTrials.gov record lists 126 sites in 22 countries, 36 of them in the United States. Half, 204 people, took bezuclastinib once a day with sunitinib 37.5mg a day. The other 209 took sunitinib 37.5mg a day alone (Wagner et al., ASCO 2026, abstract 11500). The trial was open label, so patients and doctors knew the assignment, but the scans that decided progression were read by a central team who did not.

The sunitinib dose matters for anyone comparing this to their own prescription. The Sutent label's schedule for GIST is 50mg a day for 4 weeks followed by 2 weeks off. PEAK used 37.5mg every day without a break, according to its ClinicalTrials.gov record. INTRIGUE used the label schedule. Nobody has tested the combination against 50mg on and off, and the FDA label, if one comes, will say which sunitinib schedule it was studied with.

At the September 30, 2025 data cutoff, the combination had cut the risk of progression or death in half, a hazard ratio of 0.50. Tumors shrank by the trial's measure in 46% of people on the combination against 26% on sunitinib. A second measure, the time until progression on whatever treatment came next, had not been reached on the combination against 21 months on sunitinib alone. Survival data are not mature, which means the trial cannot yet say whether people live longer, only that their tumors stayed still longer.

Two groups of GIST patients were not in the trial at all. PEAK excluded tumors driven by PDGFRA mutations, the group Ayvakit was approved for in 2020. It also excluded SDH-deficient GIST, the form more common in children and young adults, which does not depend on KIT. Bezuclastinib is built to block KIT, including the exon 17 mutations that let a tumor escape imatinib, so there is no PEAK evidence for anyone whose tumor runs on something else. The Life Raft Group has pressed for years for every patient to know their mutation. This is the trial that makes the mutation report worth pulling out of the file.

One subgroup stood out enough that Cogent opened a new cohort for it. Among 32 patients with a KIT exon 9 mutation, the combination held tumors still for a median of 25.1 months. Cogent is now enrolling 40 people with that mutation who have had little or no imatinib, to test the combination as a first treatment. That cohort is part of the same PEAK record on ClinicalTrials.gov, NCT05208047, which still lists sites as recruiting.

What Does Adding Bezuclastinib Ask of the Liver?

Sunitinib already carries a boxed warning for liver injury, the strongest warning the FDA puts on a label, and the combination adds to the load. Severe rises in the liver enzymes ALT or AST, grade 3 or higher, occurred in 10.8% of people on the combination against 1.4% on sunitinib alone. Cogent reports that these were mostly lab findings without symptoms, that every grade 3 rise resolved, and that no grade 4 rise occurred. The enzyme rises led to a lower bezuclastinib dose in 12.7% of patients and stopped the drug in 3 people, or 1.5% (Cogent, May 30, 2026).

The rest of the side-effect list looks like sunitinib's own. High blood pressure of grade 3 or worse affected 29.4% on the combination and 27.4% on sunitinib alone. Low white cells ran 15.2% against 15.4%, anemia 9.3% against 4.8%, and diarrhea 7.8% against 7.2%. Treatment-related side effects led 7.4% of people to stop on the combination against 3.8% on sunitinib. Cogent describes no new kind of risk from the pairing, and the FDA's reviewers will have the full dataset the press release summarizes.

Bezuclastinib on its own, in the SUMMIT trial for systemic mastocytosis, changed hair color in 69.5% of people against 5.0% on placebo. It altered the sense of taste in 23.7%. Those figures come from a different disease at a different dose. Cogent's GIST releases do not break out hair color, so whether it shows up alongside sunitinib is a question for the label. Anyone weighing the combination can ask their oncologist how often liver tests would be drawn in the first months. That schedule, more than any single number, is what the extra drug asks of a patient.

Where Do GIST Families Find Specialists, Second Opinions and Help Paying?

GIST has an unusually organized patient community, and the group at its center began in 2000 when a handful of patients in the early Gleevec trials started sharing their experiences online. The Life Raft Group in Wayne, New Jersey runs a patient registry with members in 63 countries. The group announced in October 2026 that the registry is now listed on ClinicalTrials.gov. It also keeps a tissue bank, a GIST mentor program, and a searchable list of US GIST specialists. Its phone number is 973-837-9092, and its events calendar lists a December 8th session on a new trial for KIT-mutant GIST.

A second opinion from a sarcoma center is the step GIST groups push hardest, because GIST is rare enough that many oncologists see few cases. The Sarcoma Alliance's Hand in Hand fund, named for Suzanne Renée Leider, pays up to $1,000 toward 1 consultation with a sarcoma expert for US patients. Grants are awarded 4 times a year, according to the Life Raft Group's financial aid page updated September 24, 2026. In August 2026 the Life Raft Group joined other sarcoma advocates in Washington to press for research funding and access to care.

Paying for a second pill on top of sunitinib is the question nobody can answer until Cogent names a price, which it has not done as of November 6, 2026. The existing programs are mapped on our help paying for GIST page. Pfizer's RxPathways covers Sutent, with a co-pay card for people on commercial insurance. The PAN Foundation, now operating as TotalAssist, runs a GIST fund of up to $4,200 a year. It opens and closes through the year with a waitlist for the next opening, according to the Life Raft Group. Cogent runs an expanded access program for US patients with GIST who meet its criteria.

What Happens on November 30th, and What Follows for Bezuclastinib?

An approval, a request for more information or a refusal are the 3 possible outcomes, and the FDA can act before the date. Cogent has said it plans to launch bezuclastinib in GIST and in systemic mastocytosis in late 2026. A second application, for nonadvanced systemic mastocytosis, has its own target date of December 30, 2026. A third, for advanced systemic mastocytosis, is due June 29, 2027. By Trial Friend's reading of the labels, the GIST approval would be the first time a KIT inhibitor is cleared to be taken alongside sunitinib rather than after it.

An approval would not settle the order of GIST treatment by itself. Qinlock remains approved for the fourth line and is being tested again in the second line. That trial is limited to the KIT exon 11 and 17 or 18 mutations where INTRIGUE suggested it did best. Stivarga stays in the third line. What would change is the choice at the first fork after imatinib, where for 20 years the only question was sunitinib's dose. Our GIST trials page lists the studies open now, and the decision page is where the outcome will appear.

Questions GIST Patients Ask About Bezuclastinib and Sunitinib